Hyperphosphatemia - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 58

Hyperphosphatemia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Hyperphosphatemia - Pipeline Review, H1 2012', provides an overview of the Hyperphosphatemia therapeutic pipeline. This report provides information on the therapeutic development for Hyperphosphatemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperphosphatemia. 'Hyperphosphatemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hyperphosphatemia.
- A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hyperphosphatemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia pipeline depth and focus of Hyperphosphatemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Hyperphosphatemia Therapeutic Products under Development, Key Players in Hyperphosphatemia Therapeutics, Hyperphosphatemia Pipeline Overview, Hyperphosphatemia Pipeline, Hyperphosphatemia Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperphosphatemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hyperphosphatemia
Hyperphosphatemia Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hyperphosphatemia Therapeutics – Products under Development by Companies
Companies Involved in Hyperphosphatemia Therapeutics Development
Amgen Inc.
Novartis AG
Mitsubishi Tanabe Pharma Corporation
Panion & Bf Biotech Inc.
Spectrum Pharmaceuticals, Inc.
Cytochroma Inc.
Vifor Pharma Ltd.
Medice Arzneimittel Putter GmbH & Co. KG
Hyperphosphatemia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SBR759 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCI-196 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bixalomer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zerenex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RenaZorb - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PA21 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Phosphate Management Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nicotinamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PT20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperphosphatemia Therapeutics – Drug Profile Updates
Hyperphosphatemia Therapeutics – Discontinued Products
Hyperphosphatemia Therapeutics - Dormant Products
Hyperphosphatemia – Product Development Milestones
Featured News & Press Releases
Dec 05, 2011: Spectrum Pharmaceuticals Files Investigational New Drug Application With FDA For SPI-014
Nov 14, 2011: Keryx Biopharmaceuticals Announces Highlights From Zerenex Poster Presentations At American Society Of Nephrology Kidney Week 2011 Annual Meeting
Nov 09, 2011: Keryx Biopharmaceuticals To Present Data On Zerenex At Upcoming American Society Of Nephrology Kidney Week 2011 Annual Meeting
Sep 19, 2011: Keryx Completes Patient Enrollment In Zerenex Phase III Long-Term Study
May 02, 2011: Keryx Receives Positive Scientific Advice From European Medicines Agency For Zerenex In Hyperphosphatemia
Apr 18, 2011: Keryx Starts Phase III Program Of Ferric Citrate In Japan By Partner, Japan Tobacco And Torii Pharmaceutical
Mar 14, 2011: Astellas Submits Application For Marketing Approval Of Bixalomer For Treatment Of Hyperphosphatemia In Japan
Mar 07, 2011: Keryx Biopharmaceuticals Announces Oral Presentation Of Final Zerenex Short-Term Phase III Data At Upcoming National Kidney Foundation's 2011 Spring Clinical Meetings
Mar 07, 2011: Keryx Biopharmaceuticals Announces Oral Presentation Of Final Zerenex Short-Term Phase III Data At Upcoming National Kidney Foundation's 2011 Spring Clinical Meetings
Nov 30, 2010: Keryx's Phase III Study Of Hyperphosphatemia Drug Meets Primary And Key Secondary Endpoints
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hyperphosphatemia, H1 2012
Products under Development for Hyperphosphatemia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Amgen Inc., H1 2012
Novartis AG, H1 2012
Mitsubishi Tanabe Pharma Corporation, H1 2012
Panion & Bf Biotech Inc., H1 2012
Spectrum Pharmaceuticals, Inc., H1 2012
Cytochroma Inc., H1 2012
Vifor Pharma Ltd., H1 2012
Medice Arzneimittel Putter GmbH & Co. KG, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Hyperphosphatemia Therapeutics – Drug Profile Updates
Hyperphosphatemia Therapeutics – Discontinued Products
Hyperphosphatemia Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Hyperphosphatemia, H1 2012
Products under Development for Hyperphosphatemia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Alzheimer's Disease – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2013
• Erectile Dysfunction – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013